Vaccines is one pharmaceutical business area that is experiencing challenging commercial dynamics as patients sit out non-essential doctor visits amid the COVID-19 pandemic.
GlaxoSmithKline PLC said it expects significant impacts on sales of Shingrix in the coming months as a result. The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?